Vaccine Equity and Access to Medicines

The Intellectual Property Debate

Access to medicines is shaped by intellectual property (IP) regimes. The WTO's TRIPS Agreement (1995) established global minimum standards for patent protection, including 20-year patents on pharmaceuticals. Proponents argue patents incentivize the massive R&D investment needed for new drugs. Critics counter that patents create monopolies that price out poor countries.

The 2001 Doha Declaration affirmed that TRIPS should be interpreted to support public health, allowing compulsory licenses that let countries manufacture generics in health emergencies. During COVID-19, India and South Africa proposed a temporary TRIPS waiver for vaccines and treatments. After 18 months of negotiations, a narrow waiver was agreed in 2022 — but many argued it came too late and was too limited to make a meaningful difference.

The Manufacturing Gap

Even when IP barriers are removed, manufacturing capacity is a bottleneck. Before COVID-19, Africa manufactured less than 1% of the vaccines it consumed. The pandemic spurred efforts to build regional manufacturing capacity — including the WHO's mRNA technology transfer hub in South Africa — but building pharmaceutical manufacturing infrastructure takes years and requires sustained investment.

The contrast with India is instructive. The Serum Institute of India, the world's largest vaccine manufacturer by volume, was able to produce COVID-19 vaccines at scale because India had invested decades in building its pharmaceutical industry. This kind of capacity cannot be created overnight.

Further Reading and Application

Deepening your understanding of this topic involves connecting it to broader patterns in political science, international relations, history, and applied research. The most effective students don't treat lessons as standalone units — they actively look for connections to other topics they've studied and to current events they're following.

Active Learning Strategies

For any concept you encounter:

• Restate it in your own words: if you can't explain a concept simply to someone who has never encountered it, you don't yet understand it well enough.
• Find real-world examples: ground every abstract concept in at least two specific historical or contemporary cases.
• Identify the strongest counter-arguments: what would a careful critic say against this concept's usefulness or accuracy?
• Connect to other concepts: how does this concept relate to others you've encountered?
• Apply it to a new situation: take a current event you're following and analyze it through the lens of this concept.

Active engagement of this kind builds the analytical depth that competitive activities (MUN, debate, mock trial) and academic work (IB, AP, university-level analysis) require.

Common Pitfalls

Students often make several recurring mistakes when first engaging with new political and analytical concepts:

• Treating concepts as definitions to memorize rather than analytical tools to apply.
• Applying concepts mechanically without considering whether they actually fit the case.
• Failing to distinguish concepts that seem similar on the surface but operate differently in detail.
• Ignoring scholarly disagreement about how concepts should be understood and applied.
• Privileging recent sources over foundational ones that established the analytical framework.

Avoiding these pitfalls is part of developing the disciplined analytical thinking that political and diplomatic research rewards.

Continuing Your Study

Model Diplomat's broader curriculum connects this topic to related lessons in MUN preparation, debate skills, international relations theory, and historical research. Working through the related lessons builds the integrated understanding that single-topic study cannot produce alone. Your engagement with this material is one investment in the deeper analytical capacity that distinguishes effective practitioners from those who can only repeat what they've been told.